Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Cash & Equivalents (2016 - 2026)

Skinvisible's Cash & Equivalents history spans 15 years, with the latest figure at $2620.0 for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 74.65% to $2620.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2620.0, a 74.65% decrease, with the full-year FY2025 number at $2620.0, down 74.65% from a year prior.
  • Cash & Equivalents hit $2620.0 in Q4 2025 for Skinvisible, up from $645.0 in the prior quarter.
  • Over the last five years, Cash & Equivalents for SKVI hit a ceiling of $160336.0 in Q2 2022 and a floor of $120.0 in Q2 2025.
  • Historically, Cash & Equivalents has averaged $32712.4 across 5 years, with a median of $11501.5 in 2021.
  • Biggest five-year swings in Cash & Equivalents: plummeted 99.43% in 2023 and later surged 1063.96% in 2024.
  • Tracing SKVI's Cash & Equivalents over 5 years: stood at $66037.0 in 2021, then rose by 23.23% to $81378.0 in 2022, then plummeted by 98.91% to $888.0 in 2023, then surged by 1063.96% to $10336.0 in 2024, then tumbled by 74.65% to $2620.0 in 2025.
  • Business Quant data shows Cash & Equivalents for SKVI at $2620.0 in Q4 2025, $645.0 in Q3 2025, and $120.0 in Q2 2025.